BB Biotech's second-largest portfolio position achieves R&D breakthrough
(Thomson Reuters ONE) -
BB BIOTECH AG /
BB Biotech's second-largest portfolio position achieves R&D breakthrough
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Actelion reports successful outcome of clinical trial with Macitentan
On April 30, 2012 Actelion announced the successful conclusion of its long-term
study with Macitentan, the successor to its top-selling drug Tracleer for
patients with pulmonary arterial hypertension. The outcome of the SERAPHIN study
puts Actelion back on very solid ground. It now has a good chance of offsetting
the pending loss of patent protection for Tracleer in 2016/2017.
BB Biotech (ISIN CH0038389992) is one of Actelion's largest shareholders with an
interest of more than 3%. Actelion currently accounts for 12.9% of BB Biotech's
investment portfolio. Including the most recent markup of Actelion's share
price, BB Biotech's investment in Actelion has yielded total book profits of CHF
260 million. Despite the various setbacks encountered by the company in the
past, BB Biotech has steadfastly held on to its position in Actelion and is one
of its longest-standing shareholders. The stock is clearly undervalued after the
release of the positive trial data.
All data as of April 30, 2012, 5.30 pm.
For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Thomas Egger, telephone +41 44 267 67 09, teg(at)bellevue.ch
www.bbbiotech.com
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector with around CHF 1.2 bn in
assets under management. BB Biotech is listed in Switzerland, Germany and Italy.
Its investments are focused on listed companies that are developing and
commercializing novel medical treatments and cures. BB Biotech's investment
selection process is guided by the fundamental research and analysis of
physicians and molecular biologists. Its Board of Directors has many years of
experience in industry and science.
BB Biotech Press Release (PDF):
http://hugin.info/130285/R/1607539/509978.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BB BIOTECH AG via Thomson Reuters ONE
[HUG#1607539]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.05.2012 - 01:01 Uhr
Sprache: Deutsch
News-ID 1109415
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Schaffhausen
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 87 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BB Biotech's second-largest portfolio position achieves R&D breakthrough
"
steht unter der journalistisch-redaktionellen Verantwortung von
BB BIOTECH AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
